The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

Hahn promises transparency in the review and approval of COVID-19 vaccines.

Vaccines Advisory Committee to Meet on October 22

Under expanded FDA authorization, Gilead Sciences’ antiviral treatment for COVID-19 can be administered to all hospitalized patients.

FDA Expands EUA for Remdesivir

Roger Humphrey is executive managing director of JLL Life Sciences.

How real estate can accelerate productivity as life sciences companies prioritize COVID-19 therapeutics, vaccines, and new diagnostics R&D amidst new guidelines.

Labs on the Frontlines: Balancing Re-Entry and the Race to a COVID-19 Cure

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

The contract is valued at $106.3 million and is supported by Operation Warp Speed.

Ology Bioservices Awarded US Army Contract to Manage Production of COVID-19 Vaccines and Therapeutics

AstraZeneca has dosed the first participants in its Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of a combination of two monoclonal antibodies (mAbs) for the prevention and treatment of COVID-19.

AstraZeneca Initiates Phase I Trial of Monoclonal Antibody Combination for COVID-19

The European Commission (EC) and Moderna have concluded exploratory talks on the potential purchase of Moderna’s COVID-19 vaccine candidate for Europeans.

EC and Moderna Conclude Exploratory Talks on Vaccine Supply for Europe

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data. 

FDA Issues EUA for COVID-19 Convalescent Plasma 

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.


Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success